Polity19 September 20263 min read
Health Ministry asks States to limit stem cell therapy to approved conditions
The Union Ministry of Health and Family Welfare has issued an advisory asking all States and Union Territories to strictly regulate stem cell therapy. It may be offered as standard clinical care only for disease conditions approved by the Ministry. The advisory complies with the Supreme Court's January 2026 judgment in Yash Charitable Trust & Ors. v. Union of India, which stressed the need to penalise the unauthorised and unscientific use of stem cell therapies.
What the advisory says
In routine clinical practice, stem cell therapy can be offered only for the conditions and indications on the Ministry-approved list. Specific blood cancers and haematologic disorders are given as examples.
For autism spectrum disorder, the advisory restricts the therapeutic use of any type of stem cell to approved clinical trials. Unproven stem cell interventions for the disorder must not be marketed as standard commercial treatments.
Any clinical trial involving stem cells must follow the National Guidelines for Stem Cell Research, 2017, issued jointly by the Indian Council of Medical Research (ICMR) and the Department of Biotechnology (DBT).
Who can act against violators
The National Medical Commission (NMC) reiterated that unauthorised administration, promotion or advertisement of stem cell therapy beyond approved indications is professional misconduct under the Indian Medical Council Regulations, 2002. State Medical Councils can take disciplinary action against doctors who do so.
Establishments may face penalties and cancellation of registration under Sections 32 and 40 of the Clinical Establishments (Registration and Regulation) Act, 2010. The Act regulates hospitals and clinics and requires them to meet minimum standards of facilities and services. The advisory relies on it for registration cancellations.
Why the line is drawn there
Haematopoietic stem-cell transplantation, commonly called bone marrow transplant, is a globally accepted treatment for certain blood cancers such as leukaemia and serious blood disorders such as thalassemia. Use of stem cells for neurological conditions such as autism, Alzheimer's and Parkinson's remains highly experimental.
The therapy carries risks including tumour formation, unintended cell differentiation and immune complications. Unregulated clinics may expose patients to infections, embolisms and neurological damage. Embryonic stem-cell research also raises ethical concerns.
The 2017 guidelines provide the ethical and scientific framework for stem cell research and sort it into permitted, restricted and prohibited areas. Under the Drugs and Cosmetics Act, 1940 and the New Drugs and Clinical Trials Rules, 2019, stem cell-derived products are classified as new drugs. They need approval from the Central Drugs Standard Control Organisation (CDSCO) before commercialisation.